RE:This is nuts"Everyday we wait for Q3 I am more convinced it is going to be bad..."
Gilles said they had $10 million cash. That would be down meaningfully from last quarter's $11.3 million. Gilles said 2023 will be challenging in last months presentation. There was no sign of reordering commencing from their major client. It looks like CZO cut back on social media spending to pinch pennies. They are ramping up costs for the pipeline. Chances are the quarter is not going to look pretty. With only about one month left in the year has reordering commenced yet with CZO's largest client? What will the imminent launch of the dry powder oat beta glucan with Symrise do for revenue? With the avenanthramide malted technology now able to produce what four plants could from the same output do they have customers lined up? This technology allows CZO to reach the neutraceutical market for the first time. In last month's presentation Gilles anticipated a return to historical trends for sales in 2024. Is that what he still sees with one month now left until 2024.
With cash to execute the plan in place to key milestones...
What could CZO's stock be worth next year with:
1) Successful 10X PGX scale-up accessing the $1 billion immune booster market.
2) PGX CoQ10 licensing deal in the $4 billion CoQ10 market.
3) Successful completion of the Phase I portion of the avenanthramide clinical trial and commencement of the Phase IIa portion of the trial.
4) IND filing for the fibrosis drug that could profoundly alter the treatment landscape.
5) Successful completion of the wound healing studies.
6) Return to growth for the base business with the lauch of dry powder formulations of oat beta glucan and avenanthramide as well as the launch of the avenanthramide malting technology for neutraceutical applications.